Amubarvimab, previously known as BRII-196 , represents a significant advancement in biopharmaceutical development, particularly concerning its potential to block SARS-CoV-2 . This targeted agent demonstrates https://bookmark-dofollow.com/story28752297/amubarvimab-a-deep-analysis-into-the-antibody-s-prospects